Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 9, 2026

The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%

View original at nasdaq.com
The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8% The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 5 Hidden Yield dividend stocks are poised to deliver 15% annualized returns - enough to double investment every 5 years

    80% confidence

  • GLP-1 drugs can't put a dent in Coca-Cola despite worries from bears

    80% confidence

  • Experts estimate it would take tens of billions of dollars of investment and many years to meaningfully ramp up oil production in Venezuela

    80% confidence

  • Verizon is falling short of its potential and needs to improve loyalty, retention, and operational efficiency

    80% confidence

  • Uncertain economic environment with mixed indicators - some like GDP and PCE are strong, but housing pressure and consumer uncertainty are impacting home improvement

    80% confidence

  • Keytruda won't start to lose exclusivity until late 2028

    80% confidence

  • Dogs of the Dow strategy works because it is contrarian - high yields for blue chips signal value as these stocks are out of favor, not going out of business

    80% confidence

  • More than 10,000 rare diseases exist today but only 5% have approved medicines

    80% confidence

  • U.S. housing market is begging for investment - industry has been underbuilding for years and nearly three-quarters of existing homes are 25 years old or greater

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8% — Source | Via News | ViaNews EU